Subscribe to RSS
DOI: 10.1055/a-2713-6243
D-dimer Response to Thrombolysis vs. Anticoagulation in Acute Pulmonary Embolism: An Observational Study
Authors
Abstract
The utility of D-dimer as a dynamic biomarker for treatment response in pulmonary embolism (PE) remains unclear. This study compares changes in D-dimer and their relation to right ventricular (RV) recovery in PE patients treated with thrombolysis with alteplase (tPA) versus anticoagulation with heparin. We retrospectively analyzed 62 patients with acute PE treated with either tPA or heparin. All patients had baseline and 24-hour follow-up laboratories and echocardiography. RV function improvement was defined as a ≥15% change in tricuspid regurgitation maximum velocity (TRmax), tricuspid annular plane systolic excursion (TAPSE), right ventricle to left ventricle diameter ratio (RV/LV), and peak systolic velocity of the tricuspid annulus (S'). D-dimer levels increased significantly in the tPA group (median 2.40 to 20.0 µg/mL, p < 0.001) and decreased in the heparin group (2.42 to 1.65 µg/mL, p < 0.001). Troponin I decreased significantly after tPA but not with heparin. RV function improved in 61% of tPA patients versus 7% in the heparin group (p < 0.001) and was associated with changes in D-dimer and troponin I. In a subset of patients, follow-up computed tomography pulmonary angiography (CTPA) showed clot reduction in 90% of tPA-treated patients, compared with none in the heparin group. In the tPA group 30-day mortality was lower (9% versus 17%), although the difference was not statistically significant. tPA treatment is associated with increase in D-dimer levels, reduction in troponin I, and greater RV recovery. D-dimer may serve as a useful real-time biomarker for therapeutic response and possibly prognosis in acute PE.
Keywords
D-dimer - troponin I - pulmonary embolism - thrombolysis - anticoagulation - right ventricular recovery - echocardiographyPublication History
Received: 01 August 2025
Accepted: 29 September 2025
Article published online:
15 October 2025
© 2025. International College of Angiology. This article is published by Thieme.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Franchini M, Focosi D, Pezzo MP, Mannucci PM. How we manage a high D-dimer. Haematologica 2024; 109 (04) 1035-1045
- 2 Keller K, Beule J, Balzer JO, Dippold W. D-dimer and thrombus burden in acute pulmonary embolism. Am J Emerg Med 2018; 36 (09) 1613-1618
- 3 Ji Y, Sun B, Juggessur-Mungur KS, Li Z, Zhang Z. Correlation of D-dimer level with the radiological severity indexes of pulmonary embolism on computed tomography pulmonary angiography. Chin Med J (Engl) 2014; 127 (11) 2025-2029
- 4 Geissenberger F, Schwarz F, Probst M. et al. D-dimer predicts disease severity but not long-term prognosis in acute pulmonary embolism. Clin Appl Thromb Hemost 2019; 25: 1076029619863495
- 5 Knecht MF, Heinrich F, Spanuth E. Evaluation of plasma D-dimer in the diagnosis and in the course of fibrinolytic therapy of deep vein thrombosis and pulmonary embolism. Thromb Res 1992; 67 (02) 213-220
- 6 Martin C, Sobolewski K, Bridgeman P, Boutsikaris D. Systemic thrombolysis for pulmonary embolism: a review. P&T 2016; 41 (12) 770-775
- 7 Kahn SR, de Wit K. Pulmonary embolism. N Engl J Med 2022; 387 (01) 45-57
- 8 Aranda C, Peralta L, Gagliardi L, López A, Jiménez Á, Herreros B. A significant decrease in D-dimer concentration within one month of anticoagulation therapy as a predictor of both complete recanalization and risk of recurrence after initial pulmonary embolism. Thromb Res 2021; 202: 31-35
- 9 Dwivedi AK. How to write statistical analysis section in medical research. J Investig Med 2022; 70 (08) 1759-1770
- 10 Dwivedi AK, Shukla R. Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features. Cancer Rep (Hoboken) 2020; 3 (04) e1211
- 11 Piazza G, Hohlfelder B, Jaff MR. et al; SEATTLE II Investigators. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv 2015; 8 (10) 1382-1392
- 12 Dastani M, Askari VR, Nasimi Shad A, Ghorbani N, Baradaran Rahimi V. Investigating the effects of systemic thrombolysis on electrocardiography and pulmonary artery blood pressure in patients with pulmonary embolism. Health Sci Rep 2024; 7 (10) e70085
- 13 Wessinger M, Gauchel N, Strobel D. et al. Characterizing technical success and clinical outcomes in patients with pulmonary embolism treated with ultrasound-assisted catheter-directed thrombolysis (USAT): a retrospective, single-center cohort study. Clin Res Cardiol 2025; . Epub ahead of print
- 14 Kucher N, Boekstegers P, Müller OJ. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129 (04) 479-486
- 15 Rosa A, Murguia AR, Brockman MJ, Mukherjee D, Rajachandran M, Nickel NP. Low-dose systemic tissue-type-plasminogen-activator compared to conventional anti-coagulation for the treatment of intermediate-high risk pulmonary embolism. Cardiovasc Hematol Disord Drug Targets 2025; 25 (01) 46-53
- 16 Zientek E, Talkington K, Gardner J. et al. Low-dose alteplase versus conventional anticoagulation to treat submassive pulmonary embolism in Hispanic patients. Int J Angiol 2022; 32 (02) 131-135
- 17 Murguia AR, Mukherjee D, Ojha C, Rajachandran M, Siddiqui TS, Nickel NP. Reduced-dose thrombolysis in acute pulmonary embolism a systematic review. Angiology 2024; 75 (03) 208-218
- 18 Danrong Y, Yan Z, Yi L. Correlation between the transient increase of D-dimer and thrombolysis at 30d after anticoagulation therapy in patients with pulmonary embolism. Clin Appl Thromb Hemost 2025;31:10760296251335250
- 19 Speiser W, Mallek R, Koppensteiner R. et al. D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness. Thromb Haemost 1990; 64 (02) 196-201
- 20 The DVTENOX Study Group. Markers of hemostatic system activation in acute deep venous thrombosis—evolution during the first days of heparin treatment. Thromb Haemost 1993; 70 (06) 909-914
- 21 Couturaud F, Kearon C, Bates SM, Ginsberg JS. Decrease in sensitivity of D-dimer for acute venous thromboembolism after starting anticoagulant therapy. Blood Coagul Fibrinolysis 2002; 13 (03) 241-246
- 22 Estivals M, Pelzer H, Sie P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991; 78 (03) 421-424
- 23 Amelsberg A, Zurborn KH, Gärtner U, Kiehne KH, Preusse AK, Bruhn HD. Influence of heparin treatment on biochemical markers of an activation of the coagulation system. Thromb Res 1992; 66 (2-3): 121-131
- 24 Hvas CL, Larsen JB. The fibrinolytic system and its measurement: history, current uses and future directions for diagnosis and treatment. Int J Mol Sci 2023; 24 (18) 20230916
- 25 Mukhopadhyay S, Johnson TA, Duru N. et al. Fibrinolysis and inflammation in venous thrombus resolution. Front Immunol 2019; 10: 1348
- 26 Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999; 99 (02) 299-304